5-Phenoxytryptamine (5-PhO-T), also known as OVT2 or Otava 3736689, is a psychedelic drug of the tryptamine family related to 5-methoxytryptamine (5-MT; 5-MeO-T). It is the derivative of tryptamine and 5-methoxytryptamine in which there is a phenoxy group at the 5 position. The drug acts as a biased agonist of the serotonin 5-HT2A receptor, favoring Gαi signaling over Gαq and β-arrestin1 signaling, though not favoring Gαq signaling over β-arrestin2 signaling. Its affinity (Ki) for the serotonin 5-HT2A receptor is 57.5nM and its activational potency at this receptor ranges from 0.28nM to 15,800nM and efficacy ranges from 30% to 91% depending on the downstream signaling pathway. OTV2, given via intracerebroventricular injection, produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In addition, it produces long-term memory deficits that are dependent on serotonin 5-HT2A receptor activation in rodents. The drug was first described in the scientific literature by Elk Kossatz and colleagues in 2024. Other related compounds include OTV1, Met-I, and Nitro-I.
See also Substituted tryptamine 5-Benzyloxytryptamine 5-Nitrotryptamine (Nitro-I) BW-723C86
References